Autoimmune Lebererkrankungen – ein Update (Teil 1)

Zu den autoimmunen Lebererkrankungen gehören die autoimmune Hepatitis (AIH), die primär biliäre Cholangitis (PBC) und die primär sklerosierende Cholangitis (PSC). Diagnostik, Therapie und Surveillance dieser Erkrankungen sind aufwendig. Dieser Beitrag widmet sich der Versorgung der autoimmunen Lebererkrankungen mit dem Fokus auf neue klinische Aspekte über die kondensierte Darstellung der aktuellen leitliniengerechten Versorgung hinaus.

Schlüsselwörter

Immundiagnostik - autoimmune Lebererkrankung - autoimmune Hepatitis - unklare Hepatopathie

• Literatur

• 1 Schregel I, Steinmann S, Schramm C. Autoimmune Lebererkrankungen – ein Update (Teil 2). Primär biliäre Cholangitis (PBC) und primär sklerosierende Cholangitis (PSC). Gastroenterologie up2date 2022; 18: 245-260
• 2 Mileti E, Rosenthal P, Peters MG. Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children. Clin Gastroenterol Hepatol 2012; 10: 417-421.e2
• 3 Galaski J, Weiler-Normann C, Schakat M. et al. Update of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing. J Hepatol 2021; 74: 312-320
• 4 Sebode M, Weiler-Normann C, Liwinski T. et al. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol 2018; 9: 609
• 5 Schultheiß C, Steinmann S, Lohse AW. et al. B cells in autoimmune hepatitis: bystanders or central players?. Semin Immunopathol 2022; 2022: 1-17
• 6 Czaja AJ, Morshed SA, Parveen S. et al. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 1997; 26: 567-572
• 7 Hov JR, Boberg KM, Karlsen TH. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008; 14: 3781-3791
• 8 Leung PSC, Rossaro L, Davis PA. et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 2007; 46: 1436-1442
• 9 Kirstein MM, Metzler F, Geiger E. et al. Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 2015; 62: 1524-1535
• 10 Eyraud V, Chazouilleres O, Ballot E. et al. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int 2009; 29: 857-864
• 11 Sebode M, Kloppenburg A, Aigner A. et al. Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: Rising prevalences based on ICD codes, yet deficits in medical treatment. Z Gastroenterol 2020; 58: 431-438
• 12 Mieli-Vergani G, Vergani D, Czaja AJ. et al. Autoimmune hepatitis. Nat Rev Dis Prim 2018; 4: 18017
• 13 Laschtowitz A, Zachou K, Lygoura V. et al. Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. JHEP reports Innov Hepatol 2021; 3: 100321
• 14 Lüth S, Herkel J, Kanzler S. et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 2008; 42: 926-930
• 15 Taubert R, Engel B, Diestelhorst J. et al. Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology 2022; 75: 13-27
• 16 Association for the Study of the Liver E, Villa E, Bianchini M. et al. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022; 76: 1151-1184
• 17 Balitzer D, Shafizadeh N, Peters MG. et al. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol 2017; 30: 773-783
• 18 de Boer YS, van Nieuwkerk CMJ, Witte BI. et al. Assessment of the histopathological key features in autoimmune hepatitis. Histopathology 2015; 66: 351-362
• 19 Gurung A, Assis DN, McCarty TR. et al. Histologic features of autoimmune hepatitis: a critical appraisal. Hum Pathol 2018; 82: 51-60
• 20 Lohse AW, Sebode M, Bhathal PS. et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group. Liver Int 2022; 42: 1058-1069
• 21 Hennes EM, Zeniya M, Czaja AJ. et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176
• 22 Strassburg CP, Beckebaum S, Geier A. et al. S2k Leitlinie Autoimmune Lebererkrankungen: AWMF-Reg. Nr. 021-27. Z Gastroenterol 2017; 55: 1135-1226
• 23 Manns MP, Woynarowski M, Kreisel W. et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-1206
• 24 Pape S, Gevers TJG, Belias M. et al. Predniso(lo)ne dosage and chance of remission in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2019; 17: 2068-2075.e2
• 25 Lohse AW, Chazouillères O, Dalekos G. et al. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015; 63: 971-1004
• 26 Dayharsh GA, Loftus EVJ, Sandborn WJ. et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122: 72-77
• 27 Pape S, Snijders RJALM, Gevers TJG. et al. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol 2022; 76: 841-849
• 28 Lohse AW, Sebode M, Jørgensen MH. et al. Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. J Hepatol 2020; 73: 1496-1506
• 29 Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am 1995; 24: 759-786
• 30 Björnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci 2016; 17: 224
• 31 Sebode M, Reike-Kunze M, Weidemann S. et al. Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury. Br J Clin Pharmacol 2020; 86: 1406-1415
• 32 Jennings JJ, Mandaliya R, Nakshabandi A. et al. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin Drug Metab Toxicol 2019; 15: 231-244
• 33 Björnsson HK, Gudmundsson DO, Björnsson ES. Liver injury caused by oral anticoagulants: a population-based retrospective cohort study. Liver Int Off J Int Assoc Study Liver 2020; 40: 1895-1900
• 34 De Martin E, Michot J-M, Rosmorduc O. et al. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP reports Innov Hepatol 2020; 2: 100170
• 35 ERN RARE-LIVER. ERN Rare-Liver – Stellungnahme zu SARS-CoV2-Auffrischimpfungen. 2021. Im Internet (Stand: 20.08.2022): https://rare-liver.eu/news/detail/ern-rare-liver-statement-on-sars-cov2-booster-vaccinations
• 36 Decaux G, Prospert F, Horsmans Y. et al. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000; 135: 256-262
• 37 Candels LS, Rahim MN, Shah S. et al. Towards personalised medicine in autoimmune hepatitis: measurement of thiopurine metabolites results in higher biochemical response rates. J Hepatol 2021; 75: 324-332
• 38 van Gerven NMF, Verwer BJ, Witte BI. et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 2014; 49: 1245-1254
• 39 Hartl J, Ehlken H, Weiler-Normann C. et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol 2015; 62: 642-646
• 40 Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int Off J Int Assoc Study Liver 2003; 23: 116-123
• 41 Marjot T, Buescher G, Sebode M. et al. SARS-CoV-2 infection in patients with autoimmune hepatitis. J Hepatol 2021; 74: 1335
• 42 Duengelhoef P, Hartl J, Rüther D. et al. SARS‐CoV‐2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. United Eur Gastroenterol J 2022; 10: 319
• 43 Ehlken H, Lohse AW, Schramm C. Transient elastography in primary sclerosing cholangitis-the value as a prognostic factor and limitations. Gastroenterology 2014; 147: 542-543
• 44 Singh S, Fujii LL, Murad MH. et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2013; 11: 1573-1579
• 45 Hartl J, Denzer U, Ehlken H. et al. Transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis. J Hepatol 2016; 65: 769-775
• 46 Valean S, Acalovschi M, Dumitrascu DL. et al. Hepatocellular carcinoma in patients with autoimmune hepatitis – a systematic review of the literature published between 1989–2016. Med Pharm Rep 2019; 92: 99-105
• 47 Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019; 25: 659-671
• 48 Peters MG. Long-term use of azathioprine in the management of autoimmune hepatitis. Gastroenterol Hepatol (NY) 2019; 15: 277-279
• 49 Trivedi HD, Danford CJ, Goyes D. et al. Osteoporosis in primary biliary cholangitis: prevalence, impact and management challenges. Clin Exp Gastroenterol 2020; 13: 17-24
• 50 Ionele CM, Turcu-stiolica A, Subtirelu MS. et al. A systematic review and meta-analysis on metabolic bone disease in patients with primary sclerosing cholangitis. J Clin Med 2022; 11: 3807
• 51 Schmidt C, Stürznickel J, Strahl A. et al. Bone microarchitecture in patients with autoimmune hepatitis. J bone Miner Res Off J Am Soc Bone Miner Res 2021; 36: 1316-1325